術後痛治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Post-Operative Pain - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0662
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:295
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Post-Operative Pain – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain – Pipeline Review, H1 2020, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 7, 23, 13, 5, 35, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 3 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Post-Operative Pain – Overview
Post-Operative Pain – Therapeutics Development
Post-Operative Pain – Therapeutics Assessment
Post-Operative Pain – Companies Involved in Therapeutics Development
Post-Operative Pain – Drug Profiles
Post-Operative Pain – Dormant Projects
Post-Operative Pain – Discontinued Products
Post-Operative Pain – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Post-Operative Pain, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2020
Post-Operative Pain - Pipeline by Adynxx Inc, H1 2020
Post-Operative Pain - Pipeline by Algomedix Inc, H1 2020
Post-Operative Pain - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Post-Operative Pain - Dormant Projects, H1 2020
Post-Operative Pain - Discontinued Products, H1 2020

【掲載企業】

AcelRx Pharmaceuticals Inc
Adynxx Inc
Algomedix Inc
Altus Formulation Inc
AmacaThera Inc
Andros Pharmaceuticals Co Ltd
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Apsen Farmaceutica SA
Baudax Bio Inc
Bayer AG
Cadila Healthcare Ltd
Cali Pharmaceuticals LLC
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
CerSci Therapeutics Inc
Chromocell Corp
Concentric Analgesics Inc
Cytogel Pharma LLC
Dompe Farmaceutici SpA
Douleur Therapeutics Inc
DURECT Corp
Elliptical Therapeutics LLC
Esteve Pharmaceuticals SA
Euclises Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Flexion Therapeutics Inc
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
H. Lundbeck AS
Heron Therapeutics Inc
Innocoll AG
InSitu Biologics LLC
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Medical Developments International Ltd
MedinCell SA
Mundipharma International Ltd
Neokera LLC
Neumentum Inc
NeurAxon Pharma Inc
NeuroPn Therapeutics LLC
Ocular Therapeutix Inc
Orbis Biosciences Inc
Pacira BioSciences Inc
PainReform Ltd
Pharmaleads SA
Pharmazz Inc
PhytoHealth Corp
PixarBio Corp
PolyPid Ltd
Quoin Pharmaceuticals Ltd
Revogenex Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sedor Pharmaceuticals LLC
Seelos Therapeutics, Inc.
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
SteadyMed Therapeutics Inc
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Theracaine LLC
Trevena Inc
Vertex Pharmaceuticals Inc
Virpax Pharmaceuticals Inc
Vivozon Inc
Xigen SA
Yichang Humanwell Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[術後痛治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆